Conquering Diseases

Study Of An Investigational Drug For Newly Diagnosed Chronic Myeloid Leukemia


Seeking men and women with Chronic Myeloid Leukemia diagnosed within the last 3 months for a study of the effectiveness of an investigational drug compared to a Tyrosine Kinase Inhibitor (TKI) drug.


Participants in this study will either get the investigational drug or one of 4 different Tyrosine Kinase Inhibitor (TKI) drugs. Study visits are every 2 weeks for the first 3 months of the study and then every 3 months for up to 8 years.

What we're hoping for

We are studying whether and investigational drug is safe and effective for newly diagnosed Chronic Myeloid Leukemia compared to one of several Tyrosine Kinase Inhibitor (TKI) drugs.

Additional Information Identifier: NCT04971226

 Principal Investigator

Jonathan M. Gerber, MD

University of Massachusetts Medical School

 Study Contact

The Cancer  Research Office



UMMS University Campus

55 Lake Ave North 

Worcester,MA 01655